Danaher (NYSE:DHR) had its price objective increased by investment analysts at Credit Suisse Group from $260.00 to $264.00 in a note issued to investors on Thursday, AR Network reports. The brokerage presently has an “outperform” rating on the conglomerate’s stock. Credit Suisse Group’s target price points to a potential upside of 10.07% from the company’s previous close.
DHR has been the topic of several other research reports. The Goldman Sachs Group initiated coverage on shares of Danaher in a research note on Wednesday, December 2nd. They issued a “buy” rating and a $250.00 target price on the stock. Royal Bank of Canada lowered shares of Danaher from an “outperform” rating to a “sector perform” rating and lowered their target price for the stock from $273.00 to $234.00 in a report on Wednesday, November 25th. KeyCorp started coverage on Danaher in a research note on Monday, November 9th. They issued an “overweight” rating and a $280.00 price target on the stock. Robert W. Baird raised their price target on Danaher from $205.00 to $252.00 and gave the stock an “outperform” rating in a research report on Friday, October 23rd. Finally, Needham & Company LLC upped their price objective on Danaher from $209.00 to $272.00 in a report on Tuesday, October 27th. Two equities research analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company. The company has a consensus rating of “Buy” and an average price target of $225.38.
Shares of NYSE DHR opened at $239.84 on Thursday. Danaher has a 12-month low of $119.60 and a 12-month high of $248.32. The firm’s 50-day simple moving average is $225.79 and its 200 day simple moving average is $213.85. The company has a quick ratio of 1.68, a current ratio of 2.08 and a debt-to-equity ratio of 0.63. The company has a market cap of $170.38 billion, a price-to-earnings ratio of 48.55, a price-to-earnings-growth ratio of 2.83 and a beta of 0.74.
In other Danaher news, SVP Daniel Raskas sold 28,389 shares of the business’s stock in a transaction dated Friday, October 23rd. The shares were sold at an average price of $234.50, for a total transaction of $6,657,220.50. Following the sale, the senior vice president now directly owns 38,850 shares of the company’s stock, valued at approximately $9,110,325. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, CAO Robert S. Lutz sold 24,594 shares of the stock in a transaction dated Friday, October 23rd. The stock was sold at an average price of $233.19, for a total transaction of $5,735,074.86. Following the transaction, the chief accounting officer now owns 43,544 shares of the company’s stock, valued at $10,154,025.36. The disclosure for this sale can be found here. Insiders have sold 107,385 shares of company stock valued at $25,081,562 over the last ninety days. 11.70% of the stock is owned by insiders.
Several institutional investors and hedge funds have recently made changes to their positions in the company. Provident Wealth Management LLC bought a new position in Danaher during the third quarter worth about $27,000. Price Wealth LLC raised its stake in Danaher by 75.6% in the 3rd quarter. Price Wealth LLC now owns 137 shares of the conglomerate’s stock valued at $30,000 after acquiring an additional 59 shares during the period. Newfound Research LLC bought a new stake in Danaher in the 3rd quarter valued at $37,000. Atlas Private Wealth Management acquired a new stake in Danaher during the 3rd quarter valued at $41,000. Finally, Oakworth Capital Inc. boosted its position in Danaher by 48.9% during the third quarter. Oakworth Capital Inc. now owns 198 shares of the conglomerate’s stock worth $43,000 after purchasing an additional 65 shares during the period. 69.16% of the stock is owned by institutional investors.
Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The company operates through three segments; Life Sciences, Diagnostics, and Environmental & Applied Solutions. The Life Sciences segment provides mass spectrometers; cellular analysis, lab automation, and centrifugation instruments; microscopes; and genomics consumables.
Featured Story: The mechanics of the bid-ask spread in trading
Receive News & Ratings for Danaher Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Danaher and related companies with MarketBeat.com's FREE daily email newsletter.